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A B S T R A C T   
Experiencing traumatic events is unfortunately commonplace and, in some cases, may lead to the onset of 
debilitating mental health disorders, such as post-traumatic stress disorder (PTSD). Current diagnostic criteria for 
PTSD results in high depression and anxiety comorbidity. Better understanding of biological mechanisms and 
pathways underlying PTSD could aid in more accurate case identification and stratification of treatments. Recent 
meta-analysis has identified chronic PTSD to be associated with increased expression of pro-inflammatory cy-
tokines and alterations in neuronal structures which contribute to an overall reduction in brain volume. Despite 
this, there are currently no biological markers in clinical use to identify PTSD or monitor treatment. This case- 
control study (n = 40) aimed to identify differences in peripheral blood biomarkers, and biomarker combina-
tions, able to distinguish PTSD participants from controls, and examine in a biopsychosocial framework. The 
levels of 5/37 biomarkers investigated were significantly altered in the serum of PTSD participants: HDL and LDL 
cholesterol, tPA, IL-8 and EGF. Biomarkers could be used in combination with psychological criteria, in a bio-
psychosocial model, to support clinical management decisions and ensure appropriate individual treatment 
pathways.   
Introduction 
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric 
condition which may result following exposure to actual or threatened 
serious injury, death or sexual violence (American Psychiatric Associa-
tion, 2013). Pre-existing factors which contribute to PTSD susceptibility 
include female gender, prior trauma exposure, prior psychological 
problems, experience of adverse life events and lower socio-economic 
status (Brewin et al., 2000; Xue et al., 2015). Around 4% of the gen-
eral population will develop PTSD in their lifetime, but this is much 
greater in populations exposed to high levels of trauma such as military 
personnel and first responders (Bennett et al., 2004; Eiche et al., 2019; 
Hoge et al., 2014; Petrie et al., 2018). 
Defined causative events and symptom onset one month after 
exposure would typify PTSD as a condition suitable for rapid diagnosis 
and intervention; however, to date this has proved elusive. This may be 
due to difficulty differentiating post-trauma symptoms of distress that 
will self-resolve, from those that will become chronic or those which are 
non-specific from other psychiatric disorders, such as anxiety and 
depression (Germain, 2013; Milanak et al., 2019; Shalev et al., 2019; 
Visser et al., 2017). For example, experiencing insomnia immediately 
post-trauma is predictive of PTSD at one year (Germain, 2013). How-
ever, in a recent study of 2647 US adults exposed to a potentially trau-
matic event, 54.2% of the non-PTSD group experienced trauma-related 
disturbances to sleep (Milanak et al., 2019). 
One of the major limitations of DSM-5 PTSD criteria is the specificity, 
or lack thereof, of PTSD symptoms which often co-occur in a dysphoric 
type symptom factor in PTSD models and have been known to drive 
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comorbidity with depression and anxiety disorders. In response to the 
treatment challenges comorbidity represents in PTSD, the latest (11th) 
edition of the International Classification of Diseases (ICD-11) criteria 
for PTSD, due to be adopted into clinical practice from January 2022, 
has introduced changes to recognized PTSD symptomatology with the 
specific aim of reducing depression and anxiety comorbidity (World 
Health Organisation, 2018). Changes include the exclusion of symptoms 
common to all three disorders, and instead only include symptoms 
considered unique to PTSD such as intrusive memories, dissociative 
flashbacks, nightmares, avoidance of external reminders, thoughts and 
feelings associated to the event, hypervigilance and exaggerated startle 
response (Barbano et al., 2019). In addition, ICD-11 distinguishes PTSD 
from a sister disorder, complex PTSD, which is differentiated by 
repeated trauma exposure (Hyland et al., 2016). However, recent work 
comparing ICD-10 and ICD-11 criteria has noted no difference in the 
diagnosis of comorbid anxiety or depression disorders (Barbano et al., 
2019). Changes to the dimensional structure of PTSD have great clinical 
implications both for initial diagnosis as well as treatment planning. This 
is best exemplified by the introduction of DSM-5 which saw a high 
number of military personnel who previously met the criteria for PTSD 
under DSM-4, no longer meeting the DSM-5 criteria, affecting their ac-
cess to treatment and support services (Hoge et al., 2014). Examining 
the underlying biological mechanisms that lead to the manifestation of 
PTSD, depression and anxiety disorders is one potential avenue with 
promise to aid clinicians when performing differential diagnosis. 
Although there have been numerous studies into the biological 
processes that may underpin PTSD and indeed predispose, or contribute 
to its development, a defined universal alteration in biological process or 
systems has not materialised (Bandelow et al., 2017, 2016; Daskalakis 
et al., 2016; Speer et al., 2019). Due to the complex presentation of 
symptoms, it is likely that multiple biological systems are involved in 
PTSD. Previous research has posited changes in hypothalamic pituitary 
adrenal (HPA) axis functioning, chronic increase in sympathetic nervous 
system activity, increased inflammatory status and physical changes in 
neurological structures all to be associated with PTSD (Colvonen et al., 
2017; Jakovljevic, 2019; Kim et al., 2019). However, the intricacies and 
directionality of these changes are not fully understood. Much of the 
literature is conflicting, particularly regarding the activity of the HPA 
axis, where attenuation, elevation and no difference has all been 
assigned to glucocorticoid (GC) expression in PTSD (Domi-
ngo-Fernández et al., 2019; Speer et al., 2019). What has been estab-
lished through meta-analysis, is that an increase in pro-inflammatory 
cytokine expression and a decrease in brain volume, volumes of the 
hippocampus, insula and anterior cingulate is present in PTSD (Bromis 
et al., 2018; Passos et al., 2015). 
Neurobiological research into PTSD, and indeed other psychiatric 
disorders, has to date failed to yield substantial changes in treatment 
practices (Deacon, 2013). It has been suggested that a more integrated 
research approach which incorporates psychosocial as well as biomed-
ical methods, may lead to advances that improve patient care (Davies 
and Roache, 2017; Deacon, 2013; Hašto et al., 2013). In the context of 
PTSD, the success of psychotherapies, as well as the core etiology of 
PTSD, would suggest that a successful examination of the biological 
aspect of the disorder should be in the context of the psychosocial 
characteristics (Davis et al., 2011; Hašto et al., 2013; Kar, 2011). For a 
number of disorders, the biopsychosocial model seems to provide 
promise to better define the disorder and indeed improve patient out-
comes, such as depression and dementia (Becker et al., 2015; Gagliese 
et al., 2018; Schotte et al., 2006). However, application of a bio-
psychosocial approach in PTSD research has been limited (Wafa et al., 
2019). Clarifying signatures representative of underlying molecular 
pathology of PTSD is important to implement and interpret a bio-
psychosocial health model that accurately reflects PTSD (Hašto et al., 
2013; Schotte et al., 2006). Reaching such a milestone could not only 
lead to the development of new therapies, and make better use of 
existing ones, but also assist with stratifying patients presenting with 
PTSD into tailored treatment pathways, thus improving access to the 
most appropriate support services, in a timelier manner. To date, no 
clinically validated biomarker or biomarker combination has been 
found to assist in the diagnosis, treatment and management of PTSD 
(Bandelow et al., 2017, 2016; Friend et al., 2020). A biomarker tool 
which can accurately differentiate PTSD from non-PTSD would likely 
prove an essential aid to clinicians currently utilising the DSM-5, as well 
as aid in any crossover discrepancies if, and when, changes are made to 
the latent structure of PTSD moving beyond DSM-5 criteria. Symptom 
crossover and comorbidity with other neuropsychiatric disorders such as 
depression and anxiety, suggest that a single biomarker is unlikely to be 
diagnostic (Maslov et al., 2009). 
The aim of this study was to identify differential expression of a 
number of biomarkers, measurable in peripheral blood, in control and 
PTSD participants. Differential expression was investigated to determine 
whether a biomarker or combination of biomarkers, in tandem with 
clinical observations, could be used to assist clinicians in identifying 
patients at risk of PTSD, and build better biopsychosocial models. 
Materials and methods 
Study participants 
This case-control pilot study involved 40 (20 controls; 20 PTSD) age 
and sex-matched participants recruited in the US between January and 
June 2019, by Discovery Life Sciences (DLS), California USA, and Pre-
cisionMed, California, USA. Venous blood samples and a detailed clin-
ical history were collected from each study participant. The study 
conformed to all Data Use Agreements (DUA). Patient samples were de- 
identified and publicly available and are thus exempt from the 
requirement of the Institutional Review Board (IRB) approval (Exempt 
Category 4). A clinician and/or psychologist performed a clinician- 
administered PTSD scale for DSM-5 (CAPS-5) assessment on PTSD par-
ticipants (Weathers et al., 2018). CAPS-5 scores were available for all 20 
individuals with PTSD, and a PTSD checklist (PCL-5) score was available 
for the 20 control individuals (Ibrahim et al., 2018; Weathers et al., 
2013). 
Psychological assessment 
CAPS-5 assessment tool is widely used in clinical interview assess-
ments for PTSD, with demonstrated strong interrater and test-retest 
reliability (Weathers et al., 2018). Similarly, the PCL-5 self-assessment 
tool has also demonstrated strong psychometric properties such as 
strong internal consistency and test-retest reliability (Blevins et al., 
2015). CAPS-5 total symptom severity score is calculated by summing 
severity score for the 20 DSM-5 PTSD symptoms, as is PCL-5 total 
severity. A CAPS-5 or PCL-5 score of < 33 was considered negative for 
PTSD. The CAPS-5 and PCL-5 have shown strong correlation and high 
diagnostic concordance rates (Weathers et al., 2018). Therefore, the 
data in this study is presented using the assumption that both CAPS-5 
and PCL-5 methodologies are similar for identifying PTSD. 
Clinical characteristics 
Socio-demographic and clinical factors were collected from each 
participant and included age, gender, ethnicity, tobacco and alcohol use, 
BMI, pulse rate, systolic and diastolic blood pressure, current medica-
tions, comorbidities e.g. diabetes, hypertension, depression, anxiety, 
panic disorder, attention deficit disorder (ADD), bipolar disorder, sub-
stance abuse, and suicidal ideation. 
Sampling and laboratory methods 
Biomarker analyses was conducted at Randox Clinical Laboratory 
Services (RCLS) (Antrim, UK), using cytokine arrays (Randox 
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Laboratories Ltd, Crumlin, UK) for the following markers: Cytokine I 
Array: Interleukin-1α, − 1β, − 2, − 4, − 6, − 8, − 10, VEGF, EGF, TNFα, 
IFNγ, and MCP-1; Metabolic Array I: ferritin, insulin, leptin, plasmin-
ogen activator inhibitor-1 (PAI-1), and resistin; Metabolic Array II: C- 
reactive protein (CRP), adiponectin and cystatin C; Cerebral Array I: 
Brain-derived neurotropic factor (BDNF), glial fibrillary acidic protein 
(GFAP), and heart-type fatty acid-binding protein (H-FABP); Cerebral 
Array II: D-dimer, neuron specific enolase (NSE), neutrophil gelatinase- 
associated lipocalin (NGAL), and soluble tumour necrosis factor receptor 
I (sTNFR1). Arrays were run on an Evidence Investigator© analyser 
according to manufacturer’s instructions (Randox Laboratories Ltd, 
Crumlin, UK). Cholesterol (total), HDL and LDL cholesterol, homocys-
teine and iron were analysed on an Imola analyser (Randox Laboratories 
Ltd, Antrim, UK). Folic acid and vitamin B12 were analysed on a Cobas 
Analyser (Roche, Basel, Switzerland). Human tissue-type plasminogen 
activator (tPA) and human type-1 plasminogen activator inhibitor (PAI- 
1/tPA) complex ELISAs were obtained from AssayPro (St. Charles, 
Missouri, USA). Midkine ELISAs were obtained from CellMid, (Sydney, 
Australia). Assays were completed according to manufacturer’s in-
structions. The limits of detection (LOD) for the biomarkers under 
investigation were as follows: Cytokine I - IL-2 2.97 pg/ml; IL-4 2.12 pg/ 
ml; IL-6 0.12 pg/ml, IL-8 0.36 pg/ml; VEGF 3.24 pg/ml; IFNγ 0.44 pg/ 
ml; TNFα 0.59 pg/ml; IL1α 0.19 pg/ml; MCP1 3.53 pg/ml; EGF 1.04 pg/ 
ml; IL-10 0.37 pg/ml; IL-1β 0.26 pg/ml; Metabolic Array I – Ferritin 
3.27 ng/ml, insulin 2.32 µIU/ml, leptin 1.10 ng/ml, PAI-1 2.34 ng/ml, 
and resistin 1.06 ng/ml; Metabolic Array II – CRP 0.69 mg/l, adipo-
nectin 164 ng/ml, and cystatin C 60 ng/ml; Cerebral Array I – BDNF 
0.59 pg/ml, and GFAP 0.18 ng/ml; Cerebral Array II – D-dimer 2.1 ng/ 
ml, NSE 0.26 ng/ml, NGAL 17.8 ng/ml, and STNFRI 0.24 ng/ml. Direct 
HDL - cholesterol (HDL) 0.189 mmol/l (7.30 mg/dl), direct LDL – 
cholesterol (LDL) 0.189 mmol/l (7.30 mg/dl), cholesterol 0.865 mmol/l 
(33.4 mg/dl), iron 2 µmol/L, folic acid 1.2 ng/ml, homocysteine 1.74 
µmol/L and vitamin B12 100 pg/ml. AssayPro ELISA – Human tPA 
ELISA – 0.013 ng/ml and human PAI-1tPA complex ELISA – 0.05 ng/ml. 
Thirty-seven biomarkers in serum were investigated. Biomarker values 
that reported below the assay LOD were recorded as 90% of LOD. 
Statistical analyses 
Statistical analyses were performed using R Version 3.5.1, and IBM 
SPSS Statistics for Windows, Version 25.0 (IBM Corp, Armonk, New 
York) (Field et al., 2013; R Core Team, 2018). All tests were performed 
in duplicate. Continuous variables are presented as mean ± standard 
deviation (mean ± SD). Comparisons were made using the Wilcoxon 
rank sum test and Bonferroni correction for multiple biomarker testing 
(α = 0.05/37 = 0.0014). Categorical variables are presented as per-
centage (%) and were compared using a chi square (χ2) test. The Area 
Under Receiver Operator Curve (AUROC), sensitivity and specificity, 
positive and negative predictive values were calculated for each 
biomarker and biomarker combination. Correlations were performed 
using Spearman’s Rho test. 
Results 
Participant demographics 
There was no significant difference in age between the control and 
PTSD participants (39.0 ± 2.6 vs. 41.5 ± 11.0, p = 0.386, respectively) 
or male gender (50% vs. 45%, p = 0.752). However, a significant dif-
ference in ethnicity was observed; a greater proportion of study partic-
ipants in the PTSD group were non-Caucasian vs. the control group (60% 
vs. 21.2%, p = 0.013). Comparison of PTSD and control group de-
mographics are described in Table 1. 
BMI, pulse, hypertension (HTN), systolic and diastolic blood pressure 
There was no statistically significant difference in BMI, pulse rate, or 
HTN diagnosis between the control and PTSD participants. However, a 
significant increase in diastolic blood pressure was observed for PTSD 
participants (93.6 ± 13.7 vs. 79.9 ± 7.3; p = 0.010) and a trend level 
increase in systolic blood pressure (133.8 ± 19.7 vs. 122.2 ± 14.7; p =
0.055) (Table 1). 
Psychological comorbidities and medications 
Comorbid psychiatric conditions were more prevalent among the 
PTSD participants than control participants. Notably; depression (con-
trol 4/20 (20%) vs. PTSD 13/20 (65%) p = 0.004), anxiety (control 2/20 
(10%) vs. PTSD 16/20 (80%), p < 0.001) and panic disorder (control 0/ 
20 (0%) vs. PTSD 5/20 (25%), p = 0.017). PTSD participants unsur-
prisingly were prescribed more medications when compared to control 
group (3.2 ± 2.8 vs. 1.1 ± 1.4; p = 0.008, respectively). Three main 
categories of medications prescribed included anti-depressants, anti- 
anxiety, and pain management drugs. 
Social demographics 
In this study, the control participants smoked more (6.2 ± 7.6 vs. 2.3 
± 4.7 cigarettes/day, p = 0.048) and for longer periods of time (8.0 ±
7.9 vs. 3.2 ± 6.3 years, p = 0.025). Furthermore, there were more 
participants that smoked in the control vs. PTSD group (13/20 (65%) vs. 
6/20 (30%); p = 0.027, respectively). Alcohol consumption was also 
significantly greater in the control vs. PTSD group (15/20 (75%) vs. 5/ 
20 (25%); p = 0.002, respectively). However, the incidence of substance 
abuse was greater amongst PTSD participants (4/20 (25%) vs. 0/20 
(0%); p = 0.035) (Table 1). 
A greater proportion of the PTSD group were single (15/20 (75%) vs. 
3/19 (15.8%); p < 0.001, respectively), and fewer were married 
Table 1 
Biological, psychological, social demographics and clinical factors of the study 
participants.   





Biological Age (years) 39.0 ± 2.6 41.5 ± 11.0 0.386  





8/20 (40%) 0.013  
BMI 29.7 ± 7.9 27.9 ± 6.3 0.496  
Pulse 73.2 ± 10.4 78.3 ± 19.7 0.725  
Systolic BP 122.2 ± 14.7 133.8 ±
19.7 
0.055  
Diastolic BP 79.9 ± 7.3 93.6 ± 13.7 0.010  
Hypertension 4/20 (20%) 4/20 (20%) 1.000  
Diabetes 0/20 (0%) 3/20 (15%) 0.072  
Medications 1.1 ± 1.4 3.2 ± 2.8 0.008 
Psychological Depression 4/20 (20%) 13/20 
(65%) 
0.004  




ADD 0/20 (0%) 1/20 (5%) 0.311  
Bipolar Disorder 0/20 (0%) 2/20 (10%) 0.147  
Panic Disorder 0/20 (0%) 5/20 (25%) 0.017 
Social Smoker 13/20 (65%) 6/20 (30%) 0.027  
Cigarettes/day 6.2 ± 7.6 2.3 ± 4.7 0.048  
Smoking (years) 8.0 ± 7.9 3.2 ± 6.3 0.025  
Alcohol 15/20 (75%) 5/20 (25%) 0.002  
Substance Abuse 0/20 (0%) 4/20 (20%) 0.035  
Suicide ideation 0/20 (0%) 2/20 (10%) 0.147 
Continuous variables were expressed as mean ± SD or as % for categorical 
variables. The difference in continuous variables were analysed using Wilcoxon 
rank sum test, while chi square (χ2) test was used for categorical variables. A p 
< 0.05 was considered significant. BMI – body mass index; BP – blood pressure; 
ADD – attention deficit disorder. 
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compared to the control group (4/20 (20.0%) vs. 12/19 (63.2%), p =
0.006, respectively). The divorce rate was not significantly different 
between the control and PTSD group (4/19 (21.1%) vs. 1/20 (5.0%); p 
= 0.134, respectively). In addition, 2/20 (10%) PTSD participants re-
ported previous suicide attempts. This was not reported by any of the 
control participants (Table 1). 
PTSD assessment and symptom severity 
Total severity of PTSD symptoms was determined by summing the 
severity of each DSM-5 PTSD symptom clusters. Mean total severity of 
PTSD symptoms for the PTSD group was 47.7 ± 7.6. In the control 
group, mean total severity of PTSD symptoms, as assessed by PCL-5 was 
10.1 ± 7.8. Symptom severity of each individual PTSD symptom cluster 
is detailed in Table 2. The number of endorsed PTSD symptoms 
(symptoms whose severity is equal to or greater than a score of 2/4) was 
16.6 ± 1.6 and 1.8 ± 2.2 in the PTSD and control participant groups, 
respectively. 
Biomarker analysis 
In total, 37 serum biomarkers were investigated (Table 3). Five 
biomarkers (5/37 (13.5%)) were identified as significantly altered in 
PTSD participants when compared to the control group; HDL choles-
terol, LDL cholesterol, EGF, tPA and IL-8 (Table 3). LDL and HDL 
cholesterol had the highest Area Under the Receiver Operator Curve 
(AUROC) for differentiating between the control vs. PTSD group. 
However, as the study participants had not been asked to fast prior to 
their venous blood sampling, HDL and LDL cholesterol were not 
included in any further analyses. Of the remaining 3 significant bio-
markers, EGF was significantly lower in the PTSD group (13.3 ± 14.3 
pg/ml vs. 73.2 ± 35.7 pg/ml, p < 0.001) (Fig. 1A) whereas, tPA and IL-8 
were significantly elevated in PTSD; tPA (5.1 ± 2.9 ng/ml vs. 1.7 ± 0.7 
ng/ml, p < 0.001) (Fig. 1B) and IL-8 (13.0 ± 5.6 pg/ml vs. 8.1 ± 2.8 pg/ 
ml, p = 0.037) (Fig. 1C). The AUROCs of the three individual biomarkers 
and in combination are shown in Fig. 1D. 
Correlation matrix chart 
A correlation matrix chart was completed to test for correlations 
between all significant biomarkers, and between significant biomarkers 
and CAPS-5 assessed total PTSD symptom severity. EGF had the stron-
gest correlation with CAPS-5 assessed total PTSD severity (r = − 0.79). 
Other biomarker correlations identified between CAPS-5 assessed total 
PTSD severity included tPA (r = 0.59) and IL-8 (r = 0.33). Biomarker 
correlations are described in Fig. 2. 
Discussion 
Exposure to traumatic events is common in the general population 
with a lifetime rate for PTSD of approximately 4% (Frissa et al., 2013; 
Kilpatrick et al., 2013; Shalev et al., 2019). In occupations such as 
Emergency Medical Services (EMS), police, fire services and the mili-
tary, where exposure to traumatic events is more common, the lifetime 
rate for PTSD is higher than that of the general population (Eiche et al., 
2019; Hoge et al., 2014; Petrie et al., 2018). In this study, we used a 
participant cohort with a heterogeneous trauma type. Differences in 
trauma type may relate to differences in symptom severity. Therefore, 
using a heterogeneous participant cohort may prove more beneficial in 
identifying potential biological signature(s) that are common across 
PTSD. 
Comparison of baseline social and biological demographics of the 
PTSD and control participant groups identified several significant dif-
ferences. Namely, the control participants consumed more alcohol, 
smoked more, and for longer. However, alcohol abuse was more prev-
alent in the PTSD group. There is extensive literature documenting the 
Table 2 





























1.0  17.0 




1.5  13.0 
Av total 1.0 ± 1.2 5.8 ± 1.0 <
0.001  
0.5  6.0 




2.0  16.0 




4.0  11.0 
Threshold for CAPS-5/PCL-5 indication of PTSD total score 
∑
IAvCAr > 33. The 
difference in continuous variables were analysed using Wilcoxon rank sum test, 
data is presented as mean ± SD; a p < 0.05 was considered significant. 
I total – intrusion symptoms; Av total – avoidance symptoms; C total – cognitions 
and mood symptoms; Ar total – arousal and reactivity symptoms. 
Table 3 
Comparison of mean serum biomarker levels in control vs. PTSD participants.  
Biomarker Control (n = 20) PTSD (n = 20) p value 
LDL Cholesterol (mmol/l) 3.4 ± 0.9 1.3 ± 0.3 < 0.001 
HDL Cholesterol (mmol/l) 1.3 ± 0.4 3.2 ± 1.0 < 0.001 
EGF (pg/ml) 73.2 ± 35.7 13.5 ± 14.3 < 0.001 
tPA (ng/ml) 1.7 ± 0.7 5.1 ± 2.9 < 0.001 
IL-8 (pg/ml) 8.1 ± 2.8 13.0 ± 5.6 0.037 
PAI-1 (ng/ml) 35.0 ± 12.0 24.0 ± 8.1 0.111 
D-dimer (ng/ml) 50.1 ± 38.6 28.1 ± 27.9 0.222 
Cystatin C (µg/ml) 1.2 ± 0.2 1.0 ± 0.2 0.259 
Homocysteine (µmol/l) 12.5 ± 7.4 8.9 ± 2.8 1.000 
Midkine (pg/ml) 107.0 ± 42.2 482.4 ± 979.9 0.851 
Folic Acid (pg/ml) 12.7 ± 8.5 15.1 ± 5.9 1.000 
PAI-1/tPA (ng/ml) 12.4 ± 5.9 9.2 ± 5.6 1.000 
Resistin (ng/ml) 5.6 ± 2.4 4.4 ± 1.4 1.000 
IFNγ* 2/20 (10%) 10/20 (50%) 0.222 
Vitamin B12 (ng/ml) 460.5 ± 256.2 572.4 ± 292.8 1.000 
Ferritin (mg/l) 43.7 ± 36.3 79.6 ± 85.5 1.000 
GFAP (ng/ml) 0.6 ± 0.4 1.0 ± 0.7 1.000 
CRP (mg/l) 3.6 ± 4.8 8.0 ± 12.5 1.000 
Insulin (pmol/l) 34.6 ± 36.9 20.3 ± 16.3 1.000 
NGAL (ng/ml) 826.9 ± 196.6 758.5 ± 197.7 1.000 
Adiponectin (µg/ml) 4.1 ± 4.0 3.9 ± 2.3 1.000 
IL-1β (pg/ml) 1.8 ± 0.3 2.2 ± 1.0 1.000 
Leptin (mg/l) 12.9 ± 13.9 12.3 ± 14.1 1.000 
IL-4 (pg/ml) 2.6 ± 0.4 2.4 ± 0.4 1.000 
IL-1α (pg/ml) 0.5 ± 0.1 0.4 ± 0.1 1.000 
MCP-1 (pg/ml) 188.8 ± 117.3 186.2 ± 71.7 1.000 
sTNFR1 (ng/ml) 0.8 ± 0.2 0.8 ± 0.2 1.000 
IL-2 (pg/ml) 3.3 ± 0.8 3.5 ± 1.0 1.000 
Iron (µmol/l) 12.2 ± 5.2 13.2 ± 9.7 1.000 
IL-6 (pg/ml) 2.4 ± 3.0 2.7 ± 2.8 1.000 
IL-10 (pg/ml) 1.3 ± 0.2 1.7 ± 1.3 1.000 
BDNF (pg/ml) 7099.5 ± 743.9 6407.7 ± 1704.1 1.000 
VEGF (pg/ml) 80.5 ± 52.6 95.1 ± 94.8 1.000 
H-FABP (ng/ml) 1.4 ± 0.5 1.4 ± 0.7 1.000 
NSE (ng/ml) 4.0 ± 1.6 4.8 ± 3.3 1.000 
Total Cholesterol (mmol/l) 5.1 ± 1.0 5.1 ± 1.1 1.000 
TNFα (pg/ml) 2.2 ± 0.4 2.4 ± 0.8 1.000 
*IFNγ results were converted to nominal data with values below the limit of 
detection (LOD) assigned 0 and any value above the LOD assigned 1. Chi square 
(χ2) test was used for this categorical variable. Continuous variables were 
expressed as mean ± SD. Bonferroni correction for multiple testing was applied. 
A p < 0.05 was considered significant. LDL and HDL markers are reported but 
excluded from analysis as participants had not been asked to fast prior to venous 
blood sample collection. Values below the LOD were assigned a value of 90% of 
the LOD. 
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relationship between PTSD and excessive alcohol use (Angkaw et al., 
2015; Miller et al., 2017). Moreover, the hypothesis of alcohol misuse as 
‘self-medication’ to attenuate psychological suffering has gained wide 
popularity (Khantzian, 1997). However, studies investigating alcohol 
and cigarette use in chronic PTSD have reported that weekly alcohol 
consumption was substantially below that of the general population, in 
agreement with our findings (den Velde et al., 2002). 
Recent meta-analysis has identified that PTSD is associated with 
poorer lifestyle factors such as increased obesity and smoking, and these 
factors likely contribute to an increased cardiovascular disease (CVD) 
risk in this population (van den Berk-Clark et al., 2018). PTSD is also 
associated with hypertension, which further contributes to CVD risk 
(Abouzeid et al., 2012; Balint et al., 2016; Gradus et al., 2015; Scherrer 
et al., 2019; Sumner et al., 2016). Therefore, it was unsurprising that 
PTSD participants in this study presented with an elevated blood pres-
sure (BP), when compared to controls; albeit, a 24-hour ambulatory BP 
measurement would be considered a more reliable indicator of true BP. 
Comorbid psychiatric disorders such as depression and anxiety in 
patients with PTSD is often the rule rather than the exception (Price 
et al., 2019). As discussed previously, the overlap in disorder 
symptomology is likely to contribute to PTSD (Barbano et al., 2019; 
Price et al., 2019). Considering PTSD participants in this study were 
identified as such using the DSM-5 based CAPS-5 assessment, it was 
unsurprising that a high proportion had comorbid depression and 
anxiety. 
Identification of biological signatures that reflect or identify PTSD 
are dependent on understanding the pathophysiological systems which 
underly the development and progression of its pathology. The current 
thinking in the literature for PTSD has focused on dysregulation of the 
HPA-axis, its stress response and the subsequent effect this has on the 
immune system (Daskalakis et al., 2016; Kim et al., 2019; Michopoulos 
et al., 2015; Yehuda et al., 2014). The HPA-axis is the main coordinator 
of the neuroendocrine response to stress and altered levels of gluco-
corticoids (GCs) have been consistently identified in PTSD (Daskalakis 
et al., 2016; De Kloet et al., 2005; Schmidt et al., 2013; Van Zuiden et al., 
2012, 2011; Yehuda et al., 2014). Primarily a reduction in circulating 
GCs is observed in chronic PTSD, although elevations have also been 
reported (Pervanidou and Chrousos, 2012; Sarapas et al., 2011; Schmidt 
et al., 2013; Tegeler et al., 2017). Elevated GCs are likely attributable to 
differences in time since trauma, gender and sampling conditions (De 
Fig. 1. Boxplots describing serum markers significantly differentiated in control vs. PTSD participants. Panel A: EGF, Panel B: tPA, Panel C: IL-8. Panel D describes 
the AUROC curves for individual significant biomarkers and in combination. Bonferroni corrected p < 0.05 considered significant. 
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Quervain et al., 2016; Kim et al., 2019; Shirazi et al., 2015; Szeszko 
et al., 2018). Moreover, genetic studies have shown polymorphisms in 
FKBP5 gene, a functional inhibitor of the glucocorticoid receptor (GR), 
predispose children who experience trauma in early childhood to an 
increased risk of PTSD as an adult, with more severe symptoms (Binder 
et al., 2008). Low GCs may contribute to PTSD susceptibility, related to 
stressful life events. 
Decreased GC activity in chronic PTSD, in tandem with a decrease in 
parasympathetic nervous system stimulation and increased sympathetic 
nervous system activity, results in a chronic elevation of proin-
flammatory cytokines (Daskalakis et al., 2016; Kim et al., 2019). GCs 
suppress lymphocyte production and their subsequent secretion of 
proinflammatory cytokines (Boumpas et al., 1993). Therefore, 
decreased GC has been suggested to contribute to the increase in in-
flammatory biomarkers observed in PTSD (Kim et al., 2019). The results 
presented here, where PTSD patients exhibited a significant elevation in 
the proinflammatory cytokine IL-8, support these findings. Table 4. 
Cytokines can pass across the blood brain barrier by passive diffu-
sion, or by binding to and activating receptors on endothelial cells, 
which then induce local neuronal production of proinflammatory cy-
tokines (Kebir et al., 2007). This inflammation has been hypothesised to 
contribute to structural and functional impairment of areas in the brain 
of PTSD patients (Kim et al., 2019). 
Stress-related fear memories induced by GCs, are facilitated by 
BDNF, which is activated from its precursor and is dependent on the 
activity of tPA (Revest et al., 2014). The conversion of proBDNF to BDNF 
by tPA is inhibited by PAI-1 (Revest et al., 2014). In the current study, 
we observed increased levels of tPA in the PTSD group. Previous work 
has reported similar tPA findings, in an exclusively female adolescent 
PTSD population (Aksu et al., 2018). However, we did not observe any 
significant differences in the concentration of BDNF. This may be due to 
differing precursor availability as we did not measure proBDNF. 
The expression profile of tPA has been characterised in depression 
and have been observed to change following antidepressant therapies 
(Chen et al., 2017; Jiang et al., 2017). It is noteworthy that tPA and 
PAI-1 have opposite expression profiles in PTSD compared to depres-
sion, where a decrease and increase in expression has typically been 
reported, respectively (Chen et al., 2017; Jiang et al., 2017). We 
hypothesise that tPA may be providing a measure of the ability of GCs to 
enhance fear memories. 
The clinical utility of the three biomarkers (EGF, tPA and IL-8) that 
were differentially expressed between the control and PTSD group, was 
assessed individually and in combination. Combining the three bio-
markers into a single model differentiated control from PTSD and 
correctly identified all control and all PTSD patients. 
Adopting a biopsychosocial model for PTSD into clinical use would 
need to provide benefit to clinicians and also improve patient treatment 
and outcomes. One of the challenges currently faced in the PTSD diag-
nostic process is the high comorbid rate of depression and anxiety dis-
order. The new ICD-11 PTSD diagnostic criteria aims to address these 
comorbidities however, recent research has failed to provide supportive 
evidence (Barbano et al., 2019). The use of the biomarker combination 
in tandem with psychological symptomology assessment could poten-
tially improve the accuracy of PTSD diagnoses providing for more 
evidence-based treatment pathways. 
In summary, we have identified biomarkers that could be used to 
identify individuals with PTSD and potentially monitor treatment regi-
mens (Colvonen et al., 2017; Kim et al., 2019). Deployment of the bio-
markers to screen individuals with suspected PTSD could accelerate the 
diagnostic and treatment process by stratifying individuals most at risk, 
ensuring that triage is effective and that individuals receive the appro-
priate psychiatric care. The biomarker combination could aid in clari-
fying the ambiguity which often surrounds borderline cases, potentially 
reducing misdiagnoses, where psychological symptomology may pre-
sent non-specifically. 
Study limitations 
The main limitations of the study include (1) the small sample 
number of participants, (2) sampling bias (the cases and controls 
recruited for the study may not be truly representative) and (3) the use 
of the PCL-5 to assess PTSD symptoms in the control group is not a 
diagnostic tool. However PCL-5 has been shown to have an acceptable 
diagnostic concordance rate with the CAPS-5 and is regularly used in 
similar research (Ibrahim et al., 2018). Despite the limitations, the re-
sults suggest that biomarker-based models may offer clinical utility 
when diagnosing patients at potential risk of PTSD. Combining 
biomarker-based models with psychological criteria could potentially 
reduce bias, provide greater objectivity, potentially reduce under and 
over-diagnosis and stratify patients into the most appropriate treatment 
pathways. 
Conclusion 
Thirty-seven serum biomarkers were investigated to examine their 
expression profiles in control and PTSD participants. Three biomarkers 
were identified as differentially expressed in PTSD vs. control partici-
pants namely, EGF, tPA and IL-8. Current psychological criteria for PTSD 
diagnosis is hampered with high rates of comorbidities e.g. anxiety and 
depression. A biopsychosocial approach to PTSD which incorporates 
these biomarkers, psychological criteria and social factors may improve 
PTSD identification, diagnosis and treatment management. 
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Table 4 
Area Under the Receiver Operator Curve (AUROC), sensitivity and specificity, 
positive predictive value (PPV) and negative predictive value (NPV) for bio-
markers identified that differentiated control from PTSD participants.  
Biomarker AUC Sensitivity Specificity PPV (%) NPV (%) 
EGF (pg/ml)  0.965  0.950  0.900  90.5  94.7 
tPA (ng/ml)  0.920  0.850  0.900  89.5  85.7 
IL-8 (pg/ml)  0.803  0.750  0.800  78.9  76.2  
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